October 17, 2018 / 6:35 AM / a month ago

BRIEF-Roche CEO Says Confident In Ability To Sustain Growth Beyond 2018

Oct 17 (Reuters) - Roche Holding AG:

* SHARES SEEN RISING 1.9 PERCENT AFTER Q3 RESULTS - PREMARKET INDICATORS

* CEO SAYS CONFIDENT IN ABILITY TO CONTINUE GROWTH BEYOND 2018

* CEO SAYS NO PLANS TO CUT JOBS IN SWITZERLAND, HEAD COUNT HAS REMAINED STABLE OVER FIRST NINE MONTHS OF 2018

* DRUGS HEAD SAYS CONTINUES TO BELIEVE THAT HERCEPTIN EROSION DUE TO BIOSIMILARS WILL MIRROR RITUXAN’S SALES DECLINE

* DRUGS HEAD EXPECTS MABTHERA/RITUXAN BIOSIMILARS TO ENTER IN US IN FIRST HALF OF 2019, HERCEPTIN BIOSIMILARS IN 2ND HALF OF 2019

* DRUGS HEAD EXPECTS PERJETA, KADCYLA TO ENABLE COMPANY TO GROW HER2 FRANCHISE THROUGH ENTRY OF HERCEPTIN BIOSIMILARS

* DRUGS HEAD SAYS RETURN RATES FOR OCREVUS PATIENTS IN MS ARE WITHIN RANGE OF EXPECTATIONS

* DRUGS HEAD SAYS EXPECTS GROWTH IN CHINA TO CONTINUE AS MORE MEDICINES APPROVED Source text for Eikon: Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below